Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
RARE

RARE - Ultragenyx Pharmaceutical Inc Stock Price, Fair Value and News

37.42USD-2.38 (-5.98%)Market Closed

Market Summary

RARE
USD37.42-2.38
Market Closed
-5.98%

RARE Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

RARE Stock Price

View Fullscreen

RARE RSI Chart

RARE Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-5.07

Price/Sales (Trailing)

7.03

EV/EBITDA

-5.12

Price/Free Cashflow

-5.86

RARE Price/Sales (Trailing)

RARE Profitability

Operating Margin

88.59%

EBT Margin

-139.00%

Return on Equity

-437.28%

Return on Assets

-46.93%

Free Cashflow Yield

-17.07%

RARE Fundamentals

RARE Revenue

Revenue (TTM)

442.6M

Rev. Growth (Yr)

8.3%

Rev. Growth (Qtr)

-14.57%

RARE Earnings

Earnings (TTM)

-613.4M

Earnings Growth (Yr)

-4.09%

Earnings Growth (Qtr)

-38.55%

Breaking Down RARE Revenue

Last 7 days

-9.6%

Last 30 days

-10.6%

Last 90 days

-20.4%

Trailing 12 Months

-22.5%

How does RARE drawdown profile look like?

RARE Financial Health

Current Ratio

2.43

RARE Investor Care

Shares Dilution (1Y)

17.40%

Diluted EPS (TTM)

-7.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024442.6M000
2023383.9M402.9M410.2M434.2M
2022331.9M334.3M343.4M363.3M
2021334.1M359.4M359.6M351.4M
2020121.9M159.4M215.1M271.0M
201959.0M70.3M84.4M103.7M
201813.0M25.8M37.3M51.5M
201700331.0K2.4M
20160322.0K370.0K282.0K
20140331.0K00
20130000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ultragenyx Pharmaceutical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
parschauer karah herdman
sold
-441,270
45.00
-9,806
evp and chief legal officer
Jun 10, 2024
sanders corazon (corsee) d.
sold
-71,390
41.1
-1,737
-
May 02, 2024
crombez eric
sold
-15,455
43.66
-354
evp and chief medical officer
Apr 18, 2024
crombez eric
sold
-6,262
44.1
-142
evp and chief medical officer
Apr 16, 2024
huizenga theodore alan
sold (taxes)
-592
42.31
-14.00
svp, chief accounting officer
Mar 11, 2024
kassberg thomas richard
sold
-574,644
49.93
-11,509
cbo & evp
Mar 07, 2024
fust matthew k
sold
-620,443
50.8768
-12,195
-
Mar 01, 2024
crombez eric
sold
-66,554
53.76
-1,238
evp and chief medical officer
Mar 01, 2024
harris erik
sold
-256,328
53.76
-4,768
evp & chief commercial officer
Mar 01, 2024
kakkis emil d
sold (taxes)
-935,119
53.69
-17,417
president & ceo

1–10 of 50

Which funds bought or sold RARE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-85,000
2,660,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
691,000
691,000
0.01%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
4,622,310
4,622,310
0.02%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.48
284,496
738,496
0.09%
May 17, 2024
Artal Group S.A.
new
-
8,307,640
8,307,640
0.21%
May 16, 2024
COMERICA BANK
added
4.36
1,239
64,889
-%
May 16, 2024
Motley Fool Asset Management LLC
reduced
-1.95
-305,065
6,841,300
0.44%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.45
-211,384
3,474,340
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-45.79
-2,717,290
3,055,300
-%
May 15, 2024
Laurion Capital Management LP
new
-
3,174,920
3,174,920
0.03%

1–10 of 42

Are Funds Buying or Selling RARE?

Are funds buying RARE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RARE
No. of Funds

Unveiling Ultragenyx Pharmaceutical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
4.2%
3,453,460
SC 13G/A
Feb 14, 2024
rtw investments, lp
8.4%
6,887,086
SC 13G/A
Feb 13, 2024
vanguard group inc
10.56%
8,673,432
SC 13G/A
Feb 13, 2024
sands capital management, llc
5.0%
4,118,008
SC 13G
Feb 08, 2024
wellington management group llp
5.38%
4,415,029
SC 13G/A
Jan 29, 2024
blackrock inc.
6.4%
5,238,400
SC 13G/A
Sep 11, 2023
vanguard group inc
10.12%
7,236,523
SC 13G/A
Feb 14, 2023
rtw investments, lp
5.7%
3,966,915
SC 13G
Feb 14, 2023
price t rowe associates inc /md/
5.8%
4,096,388
SC 13G/A
Feb 09, 2023
vanguard group inc
9.09%
6,374,230
SC 13G/A

Recent SEC filings of Ultragenyx Pharmaceutical Inc

View All Filings
Date Filed Form Type Document
Jun 17, 2024
8-K
Current Report
Jun 14, 2024
424B5
Prospectus Filed
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
424B5
Prospectus Filed
Jun 12, 2024
8-K
Current Report
Jun 12, 2024
8-K
Current Report
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 10, 2024
4
Insider Trading
May 30, 2024
8-K
Current Report

Peers (Alternatives to Ultragenyx Pharmaceutical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Ultragenyx Pharmaceutical Inc News

Latest updates
MarketBeat15 hours ago
The Santa Rosa Press Democrat14 Jun 202407:05 pm
Markets Insider13 Jun 202405:42 pm
TradingView13 Jun 202412:00 pm
Yahoo Finance13 Jun 202409:12 am

Ultragenyx Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-14.6%108,833,000127,392,00098,052,000108,309,000100,496,000103,348,00090,703,00089,343,00079,935,00083,389,00081,647,00086,975,00099,395,00091,542,00081,470,00061,709,00036,309,00035,593,00025,800,00024,149,00018,172,000
Cost Of Revenue45.5%17,533,00012,051,00010,987,0009,914,00012,257,0005,319,0008,631,0008,270,0006,100,0003,509,0004,175,0003,136,0005,188,0005,481,0002,348,0001,803,000-3,503,0005,107,0002,683,000766,000452,000
Operating Expenses------------169,751,000205,964,000187,623,000131,785,000124,764,000156,974,000130,045,000143,833,000136,623,000117,386,000
  S&GA Expenses1.7%78,160,00076,833,00074,917,00081,403,00076,646,00072,849,00069,841,00068,137,00067,312,00059,431,00053,883,00053,410,00053,258,00051,042,00042,123,00042,252,00047,516,00041,877,00041,006,00039,812,00038,829,000
  R&D Expenses11.2%178,487,000160,557,000157,245,000164,949,000165,698,000170,808,000237,297,000154,529,000143,155,000123,013,000113,417,000113,205,000147,518,000175,080,50087,314,00080,709,00025,000,00083,061,000100,144,00096,045,00078,105,000
EBITDA Margin1.4%-1.32-1.34-1.49-1.72-1.81-1.88-1.90-1.46-1.37-1.25-0.95-0.94---------
Income Taxes112.3%455,000-3,702,000650,000732,000495,000-1,451,0006,287,000302,000558,00020,000182,000463,000379,00070,000313,000415,000409,0002,561,000293,000213,000216,000
Earnings Before Taxes-34.2%-170,229,000-126,892,000-158,999,000-159,096,000-163,477,000-153,284,000-238,819,000-157,860,000-151,762,000-122,438,000-72,816,000-121,965,000-135,762,000-23,941,000-68,532,00025,730,000-118,616,000-91,244,000-112,701,000-98,959,000-96,540,000
EBT Margin0.8%-1.39-1.40-1.55-1.77-1.86-1.93-1.95-1.51-1.41-1.29-0.99-0.97---------
Net Income-38.6%-170,684,000-123,190,000-159,649,000-159,828,000-163,972,000-151,833,000-245,106,000-158,162,000-152,320,000-122,458,000-72,998,000-122,428,000-136,141,000-24,011,000-68,845,00025,315,000-119,025,000-93,805,000-112,994,000-99,172,000-96,756,000
Net Income Margin0.8%-1.39-1.40-1.55-1.79-1.87-1.95-1.97-1.51-1.42-1.29-0.99-0.98---------
Free Cashflow-126.8%-193,938,000-85,504,000-121,569,000-130,099,000-181,901,000-117,312,000-121,391,000-108,180,000-149,705,000-70,392,000-80,209,000-85,427,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-12.3%1,3071,4911,2381,3111,3831,5451,6181,3211,3841,5221,4851,5121,5981,7601,2681,3141,2331,1358809591,008
  Current Assets-18.6%5967325997027668841,0136797088578479491,0711,295872906894851613699787
    Cash Equivalents-47.4%11221473.0010286.00133392160154308198291384714197336298434123131270
  Inventory5.7%36.0034.0032.0028.0027.0027.0022.0021.0018.0016.0015.0015.0012.0013.0014.0011.0011.0012.0014.0014.0011.00
  Net PPE-1.9%28529129728927826023520717714111910588.0074.0049.0048.0048.0044.0032.0025.0022.00
  Goodwill0%44.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.0044.00
Liabilities-4.0%1,1671,2161,2061,1821,1631,1931,150643588600551540543605602618624482153139121
  Current Liabilities-12.4%24628025424421826122722116718113612712719020122019710390.0075.0067.00
Shareholder's Equity-49.1%14027532.001292203524696787969239349721,0551,154666696609654727820887
  Retained Earnings-5.0%-3,558-3,387-3,264-3,104-2,944-2,781-2,629-2,384-2,225-2,073-1,951-1,878-1,755-1,619-1,595-1,526-1,552-1,433-1,339-1,226-1,127
  Additional Paid-In Capital1.0%3,6993,6623,2983,2373,1693,1403,1083,0713,0292,9972,8852,8502,8102,7732,2612,2212,1632,0872,0662,0462,014
Shares Outstanding0.9%83.0082.0072.0071.0070.0070.0070.0070.0070.0068.0068.0067.00---------
Float----3,100---3,300---6,500---4,700---2,700-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-127.3%-190-83.90-117-116-156-90.34-95.34-77.26-117-54.34-59.65-65.36-159-62.45-61.9787.00-95.15-72.04-88.51-89.06-95.77
  Share Based Compensation------------------20.0020.0022.0020.00
Cashflow From Investing188.2%94.00-10764.0099.00111-171-16179.00-37.3669.00-40.76-41.25-18298.00-95.76-86.14-95.1267.0079.00-58.43-101
Cashflow From Financing-100.0%-0.0633125.0033.00-0.722.004926.002.0086.008.0013.0013.0049019.0036.0056.003151.009.00354
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RARE Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 108,833$ 100,496
Operating expenses:  
Cost of sales17,53312,257
Research and development178,487165,698
Selling, general and administrative78,16076,646
Total operating expenses274,180254,601
Loss from operations(165,347)(154,105)
Interest income8,8246,290
Change in fair value of equity investments3,746(334)
Non-cash interest expense on liabilities for sales of future royalties(15,847)(15,636)
Other income (expense)(1,605)308
Loss before income taxes(170,229)(163,477)
Provision for income taxes(455)(495)
Net loss$ (170,684)$ (163,972)
Net loss per share, basic$ (2.03)$ (2.33)
Net loss per share, diluted$ (2.03)$ (2.33)
Shares used in computing net loss per share, Basic84,286,29270,368,478
Shares used in computing net loss per share, Diluted84,286,29270,368,478
Product sales  
Revenues:  
Total revenues$ 62,489$ 44,229
Royalty revenue  
Revenues:  
Total revenues46,3444,882
Collaboration and license  
Revenues:  
Total revenues$ 0$ 51,385

RARE Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 112,250$ 213,584
Marketable debt securities299,830363,625
Accounts receivable, net100,25373,390
Inventory35,90733,969
Other assets47,72747,616
Total current assets595,967732,184
Property, plant, and equipment, net285,111290,566
Marketable debt securities156,581199,901
Intangible assets, net165,045166,271
Goodwill44,40644,406
Other assets59,97057,685
Total assets1,307,0801,491,013
Current liabilities:  
Accounts payable40,97242,114
Accrued liabilities149,133196,486
Lease liabilities12,78112,595
Liabilities for sales of future royalties42,68929,242
Total current liabilities245,575280,437
Lease liabilities27,97930,574
Deferred tax liabilities30,05830,058
Liabilities for sales of future royalties848,725862,325
Other liabilities14,47912,205
Total liabilities1,166,8161,215,599
Stockholders’ equity:  
Preferred stock, par value of $0.001 per share -25,000,000 shares authorized; nil outstanding as of outstanding in 2024 and in 202300
Common stock, par value of $0.001 per share-250,000,00 shares authorized: outstanding-83,094,037 in 2024 and 82,315,590 in 20238382
Treasury stock, at cost, 63,575 in 2024 and 9,559 in 2023(3,332)(432)
Deferred compensation obligation3,332432
Additional paid-in capital3,698,9573,662,346
Accumulated other comprehensive income (loss)(431)647
Accumulated deficit(3,558,345)(3,387,661)
Total stockholders’ equity140,264275,414
Total liabilities and stockholders’ equity$ 1,307,080$ 1,491,013
RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
 CEO
 WEBSITEultragenyx.com
 INDUSTRYBiotechnology
 EMPLOYEES1311

Ultragenyx Pharmaceutical Inc Frequently Asked Questions


What is the ticker symbol for Ultragenyx Pharmaceutical Inc? What does RARE stand for in stocks?

RARE is the stock ticker symbol of Ultragenyx Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ultragenyx Pharmaceutical Inc (RARE)?

As of Tue Jun 18 2024, market cap of Ultragenyx Pharmaceutical Inc is 3.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RARE stock?

You can check RARE's fair value in chart for subscribers.

What is the fair value of RARE stock?

You can check RARE's fair value in chart for subscribers. The fair value of Ultragenyx Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ultragenyx Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RARE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ultragenyx Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether RARE is over valued or under valued. Whether Ultragenyx Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Ultragenyx Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RARE.

What is Ultragenyx Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, RARE's PE ratio (Price to Earnings) is -5.07 and Price to Sales (PS) ratio is 7.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RARE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ultragenyx Pharmaceutical Inc's stock?

In the past 10 years, Ultragenyx Pharmaceutical Inc has provided -0.024 (multiply by 100 for percentage) rate of return.